Sequencing bortezomib with chemotherapy and targeted agents.

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

The 26S proteasome is a multicatalytic threonine protease complex that is responsible for intracellular protein turnover in eukaryotic cells. This complex degrades and processes proteins required for regulation of various cellular functions. Bortezomib is a novel proteasome inhibitor approved for therapy of multiple myeloma. Inhibition of ubiquitin-proteasome-mediated protein degradation by bortezomib leads to accumulation of its diverse substrates, including cyclins, transcriptional factors, tumor suppressor proteins, and protooncogenes. The sequelae of such profound perturbation of cellular function include cell cycle arrest and activation of apoptotic programs. As the development of this agent continues, there is interest in evaluating its interaction with other anticancer agents. This review provides an overview of selected interactions between bortezomib and other anticancer agents preclinically and in early clinical trials.

Original languageEnglish (US)
JournalClinical lung cancer.
Volume7 Suppl 2
StatePublished - Oct 1 2005

Fingerprint

Drug Therapy
Antineoplastic Agents
Tumor Suppressor Proteins
Proteasome Inhibitors
Cyclins
Eukaryotic Cells
Proteasome Endopeptidase Complex
Threonine
Ubiquitin
Cell Cycle Checkpoints
Multiple Myeloma
Proteolysis
Proteins
Peptide Hydrolases
Clinical Trials
Bortezomib
Therapeutics
ATP dependent 26S protease

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Cite this

Sequencing bortezomib with chemotherapy and targeted agents. / Adjei, Alex.

In: Clinical lung cancer., Vol. 7 Suppl 2, 01.10.2005.

Research output: Contribution to journalReview article

@article{460b55b9d6b2427397609fd321a0aeaa,
title = "Sequencing bortezomib with chemotherapy and targeted agents.",
abstract = "The 26S proteasome is a multicatalytic threonine protease complex that is responsible for intracellular protein turnover in eukaryotic cells. This complex degrades and processes proteins required for regulation of various cellular functions. Bortezomib is a novel proteasome inhibitor approved for therapy of multiple myeloma. Inhibition of ubiquitin-proteasome-mediated protein degradation by bortezomib leads to accumulation of its diverse substrates, including cyclins, transcriptional factors, tumor suppressor proteins, and protooncogenes. The sequelae of such profound perturbation of cellular function include cell cycle arrest and activation of apoptotic programs. As the development of this agent continues, there is interest in evaluating its interaction with other anticancer agents. This review provides an overview of selected interactions between bortezomib and other anticancer agents preclinically and in early clinical trials.",
author = "Alex Adjei",
year = "2005",
month = "10",
day = "1",
language = "English (US)",
volume = "7 Suppl 2",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",

}

TY - JOUR

T1 - Sequencing bortezomib with chemotherapy and targeted agents.

AU - Adjei, Alex

PY - 2005/10/1

Y1 - 2005/10/1

N2 - The 26S proteasome is a multicatalytic threonine protease complex that is responsible for intracellular protein turnover in eukaryotic cells. This complex degrades and processes proteins required for regulation of various cellular functions. Bortezomib is a novel proteasome inhibitor approved for therapy of multiple myeloma. Inhibition of ubiquitin-proteasome-mediated protein degradation by bortezomib leads to accumulation of its diverse substrates, including cyclins, transcriptional factors, tumor suppressor proteins, and protooncogenes. The sequelae of such profound perturbation of cellular function include cell cycle arrest and activation of apoptotic programs. As the development of this agent continues, there is interest in evaluating its interaction with other anticancer agents. This review provides an overview of selected interactions between bortezomib and other anticancer agents preclinically and in early clinical trials.

AB - The 26S proteasome is a multicatalytic threonine protease complex that is responsible for intracellular protein turnover in eukaryotic cells. This complex degrades and processes proteins required for regulation of various cellular functions. Bortezomib is a novel proteasome inhibitor approved for therapy of multiple myeloma. Inhibition of ubiquitin-proteasome-mediated protein degradation by bortezomib leads to accumulation of its diverse substrates, including cyclins, transcriptional factors, tumor suppressor proteins, and protooncogenes. The sequelae of such profound perturbation of cellular function include cell cycle arrest and activation of apoptotic programs. As the development of this agent continues, there is interest in evaluating its interaction with other anticancer agents. This review provides an overview of selected interactions between bortezomib and other anticancer agents preclinically and in early clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=33644693173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644693173&partnerID=8YFLogxK

M3 - Review article

C2 - 16250928

AN - SCOPUS:33644693173

VL - 7 Suppl 2

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

ER -